Needham raised the firm’s price target on Enovis (ENOV) to $70 from $62 and keeps a Buy rating on the shares. The analyst is also adding the stock to the firm’s Conviction List in place of Boston Scientific (BSX), while naming Enovis a Top Pick for 2024. Needham is citing its confidence in the company’s revenue growth and margin drivers and anticipates multiple significant top and bottom line growth drivers in 2024, including the EMPOWR Revision launch, the ARVIS 2.0 launch, and the Lima acquisition that is expected to close in early 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENOV:
- Enovis Announces Business Segment Leadership Transition Plan
- Enovis president and COO Brady Shirley to retire at end of 1Q25
- Orthofix names Massimo Calafiore President and CEO
- Enovis to participate in the 6th Annual EverCore ISI HealthCONx Conference
- Enovis price target lowered to $63 from $70 at Baird